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Available online 30 April 2011Assessment and treatment of a patient with intermittent
claudication (IC) can be challenging. Symptoms are affected
by many comorbid conditions including emotional dysfunc-
tion and clinical success is contingent on multiple factors
including the status of both limbs. Furthermore, the
outcome of intervention depends on disease location and its
extent.1 Excellent outcomes have been reported in a series
of 1000 limbs revascularized for IC in which 70% of patients
had aorto-iliac occlusive disease and only 19% of them
underwent infrainguinal intervention.2 However, in series
where most patients had multi-level or infrainguinal disease
the results were not nearly as good.3 Moreover, individuals
with aorto-iliac occlusive disease may respond differently to
conservative treatment from those with femoral popliteal,
infragenicular ormulti-level disease. Conventional reporting
standards may not accurately reflect the clinical benefit of
treatment and lack of re-intervention data could over-
estimate results. Thus, it is not surprising that there is no
credible evidence that open or endovascular treatment is
superior to conservative management.
Nordanstig and colleagues randomised all newcomers
with IC to unsupervised exercise treatment or intervention,DOI of original article: 10.1016/j.ejvs.2011.02.019.
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1078-5884/$36 ª 2011 European Society for Vascular Surgery. Publishe
doi:10.1016/j.ejvs.2011.04.015both open and endovascular. They excluded from the study
patients unable to work because of IC, those with occa-
sional numbness in the feet, and those with tibial disease.
The follow-up time was relatively short, maximum being 24
months. Considering such a study design, perhaps it is not
surprising that authors found only a small increase in QOL
in the interventional group. Even this may change since
patency can deteriorate over time. Thus, this study
confirms the need for a more patient oriented approach in
IC research. We need to identify individuals who will
benefit from primary intervention and those who may do
well with conservative management. Obviously this is not
a simple task considering the complexity of both disease
and patient. Most importantly we have to remember that
the outcome for intervention should not be worse than
natural history of the disease, which means mortality
near zero, amputation rate 5% in five years, acceptable
high initial success rate, and last but not least, durable
outcomes. Those are not easy goals to achieve with any
intervention other then conservative management. Thus,
until new evidence is presented, we should follow TASC II
recommendations and reserve infrainguinal intervention
only for those cases that fail “best” medical therapy. After
all, conservative treatment with supervised exercise and
combined pharmacotherapy is significantly less expensive
than endovascular intervention.3d by Elsevier Ltd. All rights reserved.
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